Keyword Analysis & Research: rvsv zebov vaccine
Keyword Research: People who searched rvsv zebov vaccine also searched
Search Results related to rvsv zebov vaccine on Search Engine
-
rVSV-ZEBOV vaccine - Wikipedia
https://en.wikipedia.org/wiki/RVSV-ZEBOV_vaccine
Recombinant vesicular stomatitis virus–Zaire Ebola virus (rVSV-ZEBOV), also known as Ebola Zaire vaccine live and sold under the brand name Ervebo, is an Ebola vaccine for adults that prevents Ebola caused by the Zaire ebolavirus. When used in ring vaccination, rVSV-ZEBOV has shown a high level
DA: 26 PA: 52 MOZ Rank: 16
-
Ebola Vaccine: Information about ERVEBO - Centers for Disease …
https://www.cdc.gov/vhf/ebola/clinicians/vaccine/index.html
ERVEBO® (Ebola Zaire Vaccine, Live also known as V920, rVSVΔG-ZEBOV-GP or rVSV-ZEBOV) is approved by the U.S. Food and Drug Administration (FDA) for the prevention of disease caused by Zaire ebolavirus in individuals 18 years of age and older as a single dose administration. ERVEBO is a replication-competent, live, attenuated recombinant vesicular ...
ERVEBO® (Ebola Zaire Vaccine, Live also known as V920, rVSVΔG-ZEBOV-GP or rVSV-ZEBOV) is approved by the U.S. Food and Drug Administration (FDA) for the prevention of disease caused by Zaire ebolavirus in individuals 18 years of age and older as a single dose administration. ERVEBO is a replication-competent, live, attenuated recombinant vesicular ...
DA: 29 PA: 79 MOZ Rank: 41
-
Durability of single-dose rVSV-ZEBOV vaccine responses: what do …
https://pubmed.ncbi.nlm.nih.gov/30422031/
Abstract Introduction: The live-attenuated recombinant vesicular stomatitis virus vaccine expressing the glycoprotein (GP) of Zaire Ebola virus (rVSV-ZEBOV) has proven immunogenic in humans and effective in field studies. Yet long-term durability of vaccine responses is unknown. Author: Angela Huttner, Claire-Anne Siegrist Publish Year: 2018
Author: Angela Huttner, Claire-Anne Siegrist
Publish Year: 2018
DA: 67 PA: 61 MOZ Rank: 22
-
rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular …
https://pubmed.ncbi.nlm.nih.gov/31384731/
Jan 29, 2019 · The rVSV-ZEBOV vaccine is a live, replication competent vector in which the VSV glycoprotein (G) gene is replaced with the glycoprotein (GP) gene of ZEBOV. Multiple copies of GP are expressed and assembled into the viral envelope responsible for inducing protective immunity. Author: Thomas P. Monath, Patricia E. Fast, Kayvon Modjarrad, David K. Clarke, Brian K. Martin, Joan Fusco, ... Publish Year: 2019
Author: Thomas P. Monath, Patricia E. Fast, Kayvon Modjarrad, David K. Clarke, Brian K. Martin, Joan Fusco, ...
Publish Year: 2019
DA: 76 PA: 98 MOZ Rank: 63
-
Ebola Vaccines - National Institute of Allergy and Infectious Diseases
https://www.niaid.nih.gov/diseases-conditions/ebola-vaccines
The rVSV-ZEBOV vaccine uses a genetically engineered version of vesicular stomatitis virus (VSV), an animal virus that primarily affects cattle, to carry an Ebola virus gene insert. Experts at the Public Health Agency of Canada originally developed the vaccine, which is now licensed to Merck. NIAID and the Walter Reed Army Institute of Research (WR...
The rVSV-ZEBOV vaccine uses a genetically engineered version of vesicular stomatitis virus (VSV), an animal virus that primarily affects cattle, to carry an Ebola virus gene insert. Experts at the Public Health Agency of Canada originally developed the vaccine, which is now licensed to Merck. NIAID and the Walter Reed Army Institute of Research (WR...
DA: 8 PA: 54 MOZ Rank: 19
-
Ebola virus vaccines - World Health Organization
https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/ebola-virus-vaccines
Jan 24, 2020 · The rVSV-ZEBOV vaccine constitutes the live, replication-competent VSV vector with the VSV glycoprotein G gene replaced by the glycoprotein gene of ZEBOV. Deletion of the G protein, the principal Ebola virus virulence factor, causes attenuation and also removes the primary target for anti-vector immunity.
DA: 84 PA: 72 MOZ Rank: 21
-
VSV-ZEBOV Geneva Vaccine Trial - Full Text View - ClinicalTrials.gov
https://clinicaltrials.gov/ct2/show/NCT02287480
Nov 10, 2014 · The vaccine candidate VSV-ZEBOV (BPSC1001) has shown promising safety and efficacy in preventing Ebola Zaire infections in non-human primates (NHP). Before it can be assessed in large Phase IIb/3 trials in affected areas, safety data from phase 1 first-in-human trials are needed.
DA: 23 PA: 40 MOZ Rank: 47
-
ERVEBO, INN-Ebola Zaire Vaccine (rVSV∆G-ZEBOV-GP, live)
https://extranet.who.int/pqweb/file/18418459/download
Ebola Zaire Vaccine (rVSV∆G-ZEBOV-GP1,2 live, attenuated) ≥72 million pfu. 3 1. Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP) 2.
DA: 49 PA: 18 MOZ Rank: 15
-
Final trial results confirm Ebola vaccine provides high protection
https://www.who.int/news/item/23-12-2016-final-trial-results-confirm-ebola-vaccine-provides-high-protection-against-disease
Dec 23, 2016 · The vaccine, called rVSV-ZEBOV, was studied in a trial involving 11 841 people in Guinea during 2015. Among the 5837 people who received the vaccine, no Ebola cases were recorded 10 days or more after vaccination. In comparison, there were 23 cases 10 days or more after vaccination among those who did not receive the vaccine.
DA: 10 PA: 25 MOZ Rank: 73
-
Ebola vaccine - Wikipedia
https://en.wikipedia.org/wiki/Ebola_vaccine
Ebola vaccines are vaccines either approved or in development to prevent Ebola.The first vaccine to be approved in the United States was rVSV-ZEBOV in December 2019. It had been used extensively in the Kivu Ebola epidemic under a compassionate use protocol. During the early 21st century, several vaccine candidates displayed efficacy to protect nonhuman …
DA: 47 PA: 3 MOZ Rank: 17
